Edit |   |
---|---|
Antigenic Specificity | SARS-CoV-2 RBD (imdevimab biosimilar) |
Clone | imdevimab (REGN10987) |
Host Species | Recombinant |
Reactive Species | n/a |
Isotype | Human IgG |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | n/a |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti SARS-CoV-2 (2019-nCoV) RBD imdevimab (REGN10987). Casirivimab/imdevimab, sold under the brand name REGEN-COV, is an experimental medicine developed by the American biotechnology company Regeneron Pharmaceuticals. It is an artificial "antibody cocktail" designed to produce resistance against the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic. |
Immunogen | n/a |
Other Names | Anti-RBD Recombinant Antibody, Research Grade Anti SARS-CoV-2(2019-nCoV) RBD imdevimab(REGN10987), Anti-SARS-CoV-2 RBD Recombinant Antibody(Anti SARS-CoV-2(2019-nCoV) RBD imdevimab(REGN10987)), , Antibody Drug Analogues, Monoclonal Antibody, YR1632, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | n/a |
Catalog # | YR1632 |
Price | please inquire |
Order / More Info | SARS-CoV-2 RBD (imdevimab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |